Detailed analysis of serum lipids and lipoproteins from Japanese type III hyperlipoproteinemia with apolipoprotein E2/2 phenotype

Clinica Chimica Acta; International Journal of Clinical Chemistry
Yasuhiro TodoHiroshi Mabuchi

Abstract

To clarify a detailed profile of serum lipids, lipoproteins and apolipoproteins (apo) in type III hyperlipoproteinemia (HLP) with apolipoprotein E (apo E) phenotype 2/2. Nineteen consecutive Japanese type III HLP (9 men, 10 women) were studied. All had hypertriglyceridemia and 74% showed hypercholesterolemia. The degree of hyperlipidemia [total cholesterol (TC) 8.1 +/- 3.2 mmol/l, triglycerides (TG) 5.2 +/- 2.9 mmol/l] was milder than that in type III HLP in western countries. Lipoprotein fractions analyzed by ultracentrifugation showed that very low density lipoprotein cholesterol (VLDL-C) concentrations were considerably increased and that intermediate density lipoprotein cholesterol (IDL-C) concentrations were also increased, whereas low-density lipoprotein cholesterol (LDL-C) concentrations were low. Serum apo A-I, A-II and B concentrations were not increased, while apo C-II, C-III and E concentrations were considerably increased. However, the increase of apo E concentrations in the study subjects was far more pronounced than that of apo C-III, causing the ratio of apo E/C-III to be considerably higher than hyperlipidemia with other apo E phenotypes. By using this index apo E/C-III, it is possible to segregate type III HLP ...Continue Reading

References

Feb 1, 1975·Annals of Internal Medicine·J MorganrothD S Fredrickson
Nov 1, 1977·Annals of Internal Medicine·R S KushwahaJ J Hoover
Sep 22, 1992·Biochimica Et Biophysica Acta·K MoriyamaK Arakawa
Jul 1, 1973·Proceedings of the National Academy of Sciences of the United States of America·R J Havel, J P Kane
Jan 1, 1969·Metabolism: Clinical and Experimental·J Dyerberg
Jan 12, 1967·The New England Journal of Medicine·D S FredricksonR S Lees
Feb 2, 1967·The New England Journal of Medicine·D S FredricksonR S Lees
Dec 31, 1993·Clinica Chimica Acta; International Journal of Clinical Chemistry·K NakajimaE Campos
May 1, 1993·The Clinical Investigator·G FeussnerR Ziegler
May 29, 1998·Human Mutation·G FeussnerW März
Dec 20, 2000·Physiological Genomics·J M HagbergR E Ferrell
Nov 10, 2001·Annual Review of Genomics and Human Genetics·R W Mahley, S C Rall
Sep 20, 2002·Journal of Atherosclerosis and Thrombosis·Yoshiya HataUNKNOWN Working Committee on JAS Guideline for Diagnosis and Treatment of Hyperlipidemias
Apr 3, 2003·Journal of Lipid Research·Naohiko SakaiYuji Matsuzawa
Sep 1, 1955·The Journal of Clinical Investigation·R J HAVELJ H BRAGDON

❮ Previous
Next ❯

Citations

Jan 11, 2014·Critical Reviews in Clinical Laboratory Sciences·A D MaraisD J Blom
Mar 1, 2011·Clinica Chimica Acta; International Journal of Clinical Chemistry·Masa-aki KawashiriMasakazu Yamagishi
Dec 28, 2016·Journal of Atherosclerosis and Thrombosis·Daisuke ManitaYuji Hirowatari
Apr 8, 2020·Critical Reviews in Clinical Laboratory Sciences·Christopher S BootRobert D G Neely

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.